Targets › RECA
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.
Homologous DNA recombinase that catalyzes strand exchange, a key step in DNA repair through homologous recombination (HR). Binds to single-stranded DNA (ssDNA) in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange. (UniProt, Q06609)
Open in Phaseline: the race on RECA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Tropical Medicine, Belgium | bedaquiline ATP synthase inhibitor | RECA | Phase 3 | Leprosy | Mar 2027 |
Leprosy (1)
small molecule (1)
Institute of Tropical Medicine, Belgium (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.